Scarlet

Scarlet Therapeutics is a preclinical-stage biotechnology company developing a novel class of red blood cell-based therapies. Spun out from the University of Bristol, the company utilizes a proprietary platform to genetically engineer erythroid progenitor cells, creating "super-erythrocytes" that can carry a wide range of therapeutic proteins. These engineered cells are designed to circulate in the bloodstream for extended periods, providing sustained therapeutic activity for rare metabolic diseases and potentially autoimmune or oncological conditions. By leveraging the natural 120-day lifespan of red blood cells, Scarlet aims to improve the efficacy and safety profile of protein-based medicines compared to traditional enzyme replacement therapies. The company's lead programs target metabolic disorders such as hyperammonemia and phenylketonuria. This approach offers the potential for long-term treatment with reduced immunogenicity and improved patient outcomes.